By Vandana Singh ,
41 minutes ago Photo: Piotr Swat / Shutterstock Novo Nordisk A/S (NYSE: NVO ) on Monday outlined a broad strategic roadmap targeting sustained global expansion during its Capital Markets Day 2026 presentation.
The company reported second-quarter sales of 78.488 billion Danish kroner, up 2% year over year (+3% at constant currency).
However, the sales were down 19% from the first-quarter sales of 96.823 billion Danish kroner.
Strategy And Long-Term Growth Ambitions The company highlighted ambitious clinical goals, including plans to introduce more than five multi-blockbuster medications by 2030, and a disciplined bolt-on business development strategy.
Through these key releases, the pharmaceutical company aims to generate over 150 billion Danish kroner (around $23.06 billion) in risk-adjusted sales from its pipeline by 2035.
Read Also: Novo Nordisk, Anthropic Team Up For AI Drug Research
Management projects a 2026 to 2030 revenue compound annual growth rate matching industry peers, alongside expanding global treatment to over 60 million patients.
Operational Reset And Pipeline Diversification Novo Nordisk implemented an organizational transformation that reduced i...